Spark Therapeutics’ and Novartis Luxturna ... which is pitching to become the first approved therapy for bronchiectasis in the US. Biogen's new high-dose version of SMA drug Spinraza has started ...

Former MRC Technology drug Tysabri (natalizumab) eventually ended up as Biogen’s drug for multiple ... but prices have been sky high, such as Spark Therapeutics’ Luxturna (voretigene ...

The ClearBridge Global Value Improvers Strategy outperformed its MSCI World Value benchmark during Q4 2024. Click here to ...

Tecno has launched a new variant for its affordable Spark 30C 5G smartphone in India. The company will now be offering an 8GB memory variant, which offers double the memory of the previous 4GB ...

Sage Therapeutics has brought a lawsuit against Biogen shortly after receiving an “unsolicited” offer from its neuroscience partner. The lawsuit is sealed in Delaware’s Court of Chancery ...

Jane Grogan, Ph.D., took over Biogen’s research department in the wake of large-scale layoffs. Now, a little more than a year later, she’s making cuts of her own. The neuro-focused biotech is ...

Biogen (BIIB) and Eisai announced an update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab as treatment for early AD, or mild cognitive impairment due to ...

Sage Therapeutics (NASDAQ:SAGE) is reportedly suing Biogen (NASDAQ:BIIB) over enforcement of a standstill agreement in the wake of an unsolicited takeover bid valued at around $469M. The full ...

In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against the other healthcare stocks. McKinsey reported that, since 2019, the US healthcare industry ...